Do Not Discontinue Clopidogrel for Subconjunctival Hemorrhage
Patients with subconjunctival hemorrhage caused by clopidogrel should continue their antiplatelet therapy without interruption and be monitored for bleeding. 1, 2
Rationale for Continuing Treatment
Subconjunctival hemorrhage is classified as a minor bleeding event that does not require discontinuation of antiplatelet therapy. The Canadian Cardiovascular Society guidelines explicitly address this scenario, stating that patients receiving aspirin or aspirin and clopidogrel who develop subconjunctival bleeding should continue treatment with clinical observation (Class IIa, Level C) 1, 2.
Key Clinical Characteristics of Subconjunctival Hemorrhage
- Self-limiting condition: Resolves spontaneously within 1-2 weeks without intervention
- Does not affect visual acuity: Despite potentially dramatic appearance with complete scleral reddening
- More common with anticoagulants than antiplatelets: The bleeding risk is relatively lower with clopidogrel
- Often precipitated by: Vigorous coughing, straining during bowel movements, or minor trauma 2
When Clopidogrel Should Actually Be Stopped
The FDA label and guidelines reserve clopidogrel discontinuation for situations involving major bleeding risk or surgery with significant hemorrhagic potential 3. Specifically:
For Elective Surgery with Major Bleeding Risk:
- Discontinue 5 days before surgery (allows for dissipation of antiplatelet effect) 4, 5, 3
- Some guidelines suggest 5-7 days or even up to 7-10 days depending on bleeding risk 1, 2
- Resume as soon as hemostasis is achieved postoperatively 3
Critical Caveat - Cardiovascular Risk Assessment:
Discontinuing clopidogrel increases the risk of cardiovascular events 3. This is particularly dangerous in patients with:
- Recent coronary stent placement (especially drug-eluting stents within 12 months)
- Recent acute coronary syndrome
- High cardiovascular risk profile
For these high-risk patients, even major surgery may need to proceed with clopidogrel continued if the thrombotic risk outweighs bleeding risk 1, 2.
Clinical Management Approach
- Continue clopidogrel without interruption
- Reassure the patient that subconjunctival hemorrhage is benign and self-resolving
- Monitor for resolution over 1-2 weeks
- Investigate only if atypical features present:
Important Pitfalls to Avoid
- Do not reflexively stop clopidogrel for minor bleeding events - the cardiovascular risk of discontinuation far exceeds the minimal risk from subconjunctival hemorrhage
- Do not confuse subconjunctival hemorrhage with more serious ocular bleeding (e.g., vitreous hemorrhage, which would require different management)
- Do not substitute with heparin bridging for this indication - bridging is only considered for high-risk surgical procedures, not minor bleeding 6
The evidence consistently demonstrates that the morbidity and mortality risk from stopping clopidogrel (thrombotic events, MI, stroke) substantially outweighs the negligible risk from continuing therapy in the setting of subconjunctival hemorrhage.